PDSS1: A Potential Drug Target and Biomarker (G23590)

Target Name: PDSS1

NCBI ID: G23590

PDSS1

PDSS1: A Potential Drug Target and Biomarker

PDSS1 (Pancreatic ductal sodium channel subfamily 1) is a protein that is expressed in the pancreas, a gland that is responsible for producing insulin to regulate blood sugar levels. PDSS1 has been identified as a potential drug target for the treatment of various diseases, including diabetes.

PDSS1 is a transmembrane protein that is composed of four extracellular domains and one intracellular domain. It is expressed in the pancreas and is involved in the regulation of pancreatic ductal secretion, which is the process by which the pancreas releases enzymes and hormones into the duodenum, where they help to break down food and regulate blood sugar levels.

One of the functions of PDSS1 is to regulate the amount of salt and water that is released into the pancreatic duct during pancreatic ductal secretion. This helps to maintain a proper balance of fluids in the body and is important for maintaining the health of the pancreas itself.

PDSS1 is also involved in the regulation of the growth and differentiation of pancreatic beta cells, which are responsible for producing insulin. This is important for maintaining proper insulin production and regulation of blood sugar levels.

In addition to its functions in the pancreas, PDSS1 has also been shown to be involved in the development and progression of various diseases, including cancer. For example, studies have shown that PDSS1 is often overexpressed in various types of cancer, including pancreatic, colorectal, and breast cancer.

PDSS1 has also been identified as a potential biomarker for several diseases, including pancreatic cancer. This is because its expression is often increased in individuals with these diseases and can be used as a diagnostic or predictive marker.

The potential uses of PDSS1 as a drug target or biomarker are vast and varied. For example, PDSS1 has been shown to be a potential target for small molecule inhibitors, which could be used to treat a variety of diseases, including diabetes, cancer, and autoimmune disorders.

In addition to its potential as a drug or biomarker, PDSS1 is also of interest to researchers because of its unique structure and expression pattern. The four extracellular domains of PDSS1 are similar in sequence and composition, but the intracellular domain is different, which suggests that it may have a unique mechanism of function.

Overall, PDSS1 is a protein that is expressed in the pancreas and is involved in the regulation of pancreatic ductal secretion and the growth and differentiation of pancreatic beta cells. Its expression is often increased in various types of cancer and has been identified as a potential drug target and biomarker. Further research is needed to fully understand its functions and potential uses in the treatment of various diseases.

Protein Name: Decaprenyl Diphosphate Synthase Subunit 1

Functions: Heterotetrameric enzyme that catalyzes the condensation of farnesyl diphosphate (FPP), which acts as a primer, and isopentenyl diphosphate (IPP) to produce prenyl diphosphates of varying chain lengths and participates in the determination of the side chain of ubiquinone (PubMed:16262699). Supplies nona and decaprenyl diphosphate, the precursors for the side chain of the isoprenoid quinones ubiquinone-9 (Q9)and ubiquinone-10 (Q10) respectively (PubMed:16262699). The enzyme adds isopentenyl diphosphate molecules sequentially to farnesyl diphosphate with trans stereochemistry (PubMed:16262699)

The "PDSS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDSS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets